Sanofi: Meningitis, Meningococcal trials

The registry lists 24 Meningitis, Meningococcal studies with Sanofi as lead sponsor. 0 are open to participants now and 22 have results posted.

Phase 1 1Phase 2 7Phase 3 13Phase 4 3No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in EuropeCompletedNCT03547271Phase 3Results posted
• Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the USCompletedNCT03537508Phase 3Results posted
• Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine in ChildrenCompletedNCT03476135Phase 3Results posted
• Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in ToddlersCompletedNCT03205371Phase 3Results posted
• Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy ToddlersCompletedNCT03205358Phase 2Results posted
• Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 YearsCompletedNCT03077438Phase 3Results posted
• Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in ToddlersCompletedNCT02955797Phase 3Results posted
• Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and OlderCompletedNCT02842866Phase 3Results posted
• Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate VaccineCompletedNCT02842853Phase 3Results posted
• Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate VaccineCompletedNCT02752906Phase 3Results posted
• Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Healthy Subjects in VietnamCompletedNCT02640404Phase 2Results posted
• Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years EarlierCompletedNCT02633787Phase 4Results posted
• Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult SubjectsCompletedNCT02591290Phase 4Results posted
• Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy AdolescentsCompletedNCT02199691Phase 2Results posted
• Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and OlderCompletedNCT01732627Phase 2Results posted
• Study of a Single Dose of Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284) in Japanese SubjectsCompletedNCT01519713Phase 3Results posted
• Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial VaccinationCompletedNCT01239043Phase 2Results posted
• Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 YearsCompletedNCT00874549Phase 1/2Results posted
• Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy ToddlersCompletedNCT00483574Phase 3Results posted
• Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy ToddlersCompletedNCT00422292Phase 3Results posted
• A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy ToddlersCompletedNCT00384397Phase 3Results posted
• Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®CompletedNCT00355121Phase 2Results posted
• Postmarketing Surveillance Study for Use of Menactra® in the Republic of KoreaCompletedNCT02864927Phase 4
• Observational Safety Study of Menactra® Administered Under Standard Health Care Practice in the Russian FederationCompletedNCT02699840